Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.

Janelidze S, Teunissen CE, Zetterberg H, Allué JA, Sarasa L, Eichenlaub U, Bittner T, Ovod V, Verberk IMW, Toba K, Nakamura A, Bateman RJ, Blennow K, Hansson O. · 2021

Read Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. by Janelidze S, Teunissen CE, Zetterberg H, Allué JA, Sarasa L, Eichenlaub U, Bittner T, Ovod V, Verberk IMW, Toba K, Nakamura A, Bateman RJ, Blennow K, Hansson O. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8453354.txt.

Description

Janelidze and co-authors compare eight blood tests for amyloid-beta in Alzheimer disease head to head. A blood test for brain amyloid would be a major step for care and drug trials. Measuring amyloid in blood well proved hard for years.

The study held 408 people from two cohorts, BioFINDER and the Alzheimer Disease Neuroimaging Initiative. Each sample ran through all eight assays for the amyloid 42 to 40 ratio. Mass spectrometry methods beat immunoassays at spotting abnormal brain amyloid. Brain status was set by spinal fluid values and PET scans. The authors judge certain mass spectrometry tests ready to detect early brain pathology.

Catalog record

CREATORJanelidze S, Teunissen CE, Zetterberg H, Allué JA, Sarasa L, Eichenlaub U, Bittner T, Ovod V, Verberk IMW, Toba K, Nakamura A, Bateman RJ, Blennow K, Hansson O.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE22 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8453354

Browse the full library · About the Tower of Babel